July 9, 2018 News by Diogo Pinto #EAN2018 – Slowly Evolving Lesions Monitored Using MTR Scans May Be Marker of SPMS Progression An MRI technique known as magnetization transfer ratio (MTR) correlated closely with theĀ progression ofĀ slowly evolving lesions (SELs) ā aĀ specific type of multiple sclerosis lesion ā in patients with secondary progressive MS (SPMS). According to the researchers, monitoring changes in SELs ā which indicate demyelination and loss of nerve fibers ā…
July 9, 2018 News by Jose Marques Lopes, PhD #EAN2018 – Spinal Cord Atrophy Better Marker of Physical Disability in SPMS Than Brain Volume Loss, Study Reports Atrophy seen in areas of the spinal cord is a better predictor of physical disability in secondary progressive multiple sclerosis (SPMS) patients than loss of brain volume, a new study reports. The research was presented at theĀ 4th Congress of the European Academy of NeurologyĀ (EAN), recently held in Lisbon,…
June 22, 2018 News by Patricia Inacio, PhD #EAN2018 – MavencladĀ Greatly Reduces Risk of RRMS Relapse, Analysis Finds New retrospective analysis of the Phase 3 CLARITY study (NCT00213135)Ā shows that treatment with MavencladĀ (cladribine tablets) improved annualized relapse rate and magnetic resonance imaging (MRI) outcomes in patients with relapsing-remitting multiple sclerosis (RRMS), regardless of their age. Moreover, the effectiveness of Mavenclad was comparable to five standard therapies…
June 21, 2018 News by Patricia Inacio, PhD #EAN2018 – Both Brain and Spinal MRIs Needed to Monitor MS Inflammation, Study Says Magnetic resonance imaging (MRI) used to assess inflammation in multiple sclerosis (MS) patients should include scans of the spinal cord and not be restricted to the brain, because brain scans alone risk underestimating disease progression, a study suggests. These results were shared in the presentation, āMeasuring disease activity in…
June 21, 2018 News by Alice MelĆ£o, MSc #EAN2018 – Pupil Response to Light Linked to RRMS Duration and Severity in Study Measuring the response of the pupil to light stimulating the eye is a non-invasive and easy way to assess multiple sclerosis (MS) severity and progression, researchers report. A clinical study found that poor, or dysfunctional, pupil response was associated with longer disease duration and greater disease severity inĀ relapsing-remitting multiple…
June 20, 2018 News by Patricia Inacio, PhD #EAN2018 – Levels ofĀ Neurofilament Light Chain Can Predict Disease Progression in RRMS, Study Shows Levels ofĀ neurofilament light chain are a reliable predictor of disease worsening and progression in relapsing-remitting MS (RRMS) patients, a new study shows. Moreover, treatment withĀ GilenyaĀ (fingolimod), marketed by Novartis, can reduce the levels ofĀ NfL for up to 10 years. These findings were shared recently in the presentation ā…
June 20, 2018 News by Alice MelĆ£o, MSc #EAN2018 ā New Guidelines for MS Treatment in Europe Set by EAN, ECTRIMS New treatment guidelines for multiple sclerosis (MS) patients in Europe were set in place through an initiative undertaken by the European Academy of Neurology (EAN) and the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Launched in parallel to the 4th Congress of the European Academy…
June 19, 2018 News by Alice MelĆ£o, MSc #EAN2018 ā Ocrevus Lowers Relapse Rates Over Long Term and Better Than Rebif Does, Data Show Long-term treatment with Ocrevus (ocrelizumab) Ā ā as well as switching from Rebif (interferon beta-1a) to Ocrevus ā leads to a significant and sustained reduction in disease activity in relapsing forms of multiple sclerosis (MS). TheseĀ previouslyĀ reportedĀ findingsĀ are further supported by the latest results drawn from pooled data…
June 15, 2018 News by Alice MelĆ£o, MSc #EAN2018 – Ocrevus May Delay Progression to Wheelchair by Up to 7 Years, New Analysis of PPMS Patient Data Shows Treatment with Ocrevus (ocrelizumab) slows disability progression in primary progressive multiple sclerosis (PPMS) in ways that may be of considerable importance to patients ā including the possibility of delaying the need for a wheelchair by up to seven years, according to new data from a Phase 3…